{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:23:29Z","timestamp":1762842209327,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"vor","delay-in-days":152,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2021.100416","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T21:31:59Z","timestamp":1623187919000},"page":"100416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy"],"prefix":"10.1016","volume":"28","author":[{"given":"Christina","family":"Baik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kitty","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Santana-Davila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith D.","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2021.100416_bib0001","doi-asserted-by":"crossref","unstructured":"Mok T.S., Wu Y., Thongprasert S., et\u00a0al. Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med.. Published online 2009:947\u2013957.","DOI":"10.1056\/NEJMoa0810699"},{"issue":"27","key":"10.1016\/j.ctarc.2021.100416_bib0002","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with egfr mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100416_bib0003","article-title":"AURA 3 trial\u00a0: osimertinib +","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2021.100416_bib0004","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated egfr -mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctarc.2021.100416_bib0005","doi-asserted-by":"crossref","first-page":"viii740","DOI":"10.1093\/annonc\/mdy424.063","article-title":"Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase iii flaura study","volume":"29","author":"Ramalingam","year":"2018","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2021.100416_bib0006","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.2005.07.172","article-title":"Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group b (study 9730)","volume":"23","author":"Lilenbaum","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.ctarc.2021.100416_bib0007","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2021.100416_bib0008","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/JTO.0b013e31820cf068","article-title":"Finding alk-positive lung cancer: what are we really looking for?","volume":"6","author":"Camidge","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2021.100416_bib0009","first-page":"51","article-title":"Subsequent chemotherapy improves survival outcome in advanced non\u2013small-cell lung cancer with acquired tyrosine kinase inhibitor resistance","volume":"11","author":"Kuo","year":"2010","journal-title":"Clin. Lung Canc."},{"issue":"6","key":"10.1016\/j.ctarc.2021.100416_bib0010","first-page":"680","article-title":"Response to first-line chemotherapy in patients with non\u2013small-cell lung cancer according to epidermal growth factor receptor and k-ras mutation status","volume":"14","author":"Dong","year":"2013","journal-title":"Clin. Lung Canc."},{"key":"10.1016\/j.ctarc.2021.100416_bib0011","article-title":"M taxane monotherapy in advanced egfr mutation positive lung cancer: a single institution experience","volume":"8","author":"Baik","year":"2013","journal-title":"JTO."},{"issue":"15","key":"10.1016\/j.ctarc.2021.100416_bib0012","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.1200\/jco.2011.29.15_suppl.7551","article-title":"Survival results of a randomized, phase iii trial of nab-paclitaxel and carboplatin compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer","volume":"29","author":"Socinski","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.ctarc.2021.100416_bib0013","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non\u2013small-cell lung cancer with mutated egfr","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2021.100416_bib0014","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (wjtog3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lanc. Oncol."},{"key":"10.1016\/j.ctarc.2021.100416_bib0015","doi-asserted-by":"crossref","unstructured":"Marcoux N. MS18.03 treatment of sclc transformed from egfr mutant adenocarcinoma. J. Thorac. Oncol. Published online 2018. doi:10.1016\/j.jtho.2018.08.163.","DOI":"10.1016\/j.jtho.2018.08.163"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100416_bib0016","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of asian patients with advanced non-small-cell lung cancer harbouring egfr mutations (lux-lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lanc. Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2021.100416_bib0017","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced egfr mutation-positive non-small-cell lung cancer (optimal, ctong-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lanc. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2021.100416_bib0018","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","article-title":"First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced egfr mutation-positive non-small-cell lung cancer: analyses from the phase iii, randomized, open-label, ensure study","volume":"26","author":"Wu","year":"2015","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2021.100416_bib0019","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (impower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lanc. Oncol."},{"issue":"22","key":"10.1016\/j.ctarc.2021.100416_bib0020","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"33","key":"10.1016\/j.ctarc.2021.100416_bib0021","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated egfr-mutated advanced non-small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.ctarc.2021.100416_bib0022","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS efficacy of osimertinib in patients with t790m-positive advanced non\u2013small-cell lung cancer: data from a randomized phase iii trial (aura3)","volume":"36","author":"Wu","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100416_bib0023","doi-asserted-by":"crossref","unstructured":"Javier Cortes, Javier Rodriguez, Jose Manuel Aramendia, Esteban Salgado, Alfonso Gurpide, Jesus Garcia-Foncillas, Jose Javier Aristu, Angela Claver, Ana Bosch, Jose Maria Lopez-Picazo, Salvador Martin-Algarra, Antonio Brugarolas E.C. Front-line paclitaxel\/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncol. Published online 2003. doi:10.1159\/000066520.","DOI":"10.1159\/000066520"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100416_bib0024","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1158\/1078-0432.CCR-14-2082","article-title":"Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (brain): a nonrandomized, phase ii study","volume":"21","author":"Besse","year":"2015","journal-title":"Clin. Canc. Res."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221001143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221001143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:20:58Z","timestamp":1762842058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294221001143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":24,"alternative-id":["S2468294221001143"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100416","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100416","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100416"}}